Oncolytics Biotech Inc ONCY

Novartis and Legend Biotech Sign Exclusive License Agreemen

[askretka]

https://www.biopharminternational.com/view/novartis-and-legend-biotech-sign-exclusive-license-agreement-for-car-t-therapies

CAR-T stuff is heating up again.  Novartis T-Charge is an in vivo therapy which could be a game changer in my opinion.
It's a Phase one but if others are paying attention it could spur interest in Pelareorep. Just not sure where our BD is on CAR-T so far unfortunately. Novartis will be targeting solid Tumors with It's T-Charge platform. 

Novartis may also apply its T-Charge CAR-T cell therapy platform to the manufacture of these candidates. The platform is a next-generation CAR-T cell therapy manufacturing platform designed to preserve T cell stemness. It also facilitates CAR-T cell expansion primarily in vivo. The platform is designed to reduce the need for extensive culture time outside the body and results in T cells with greater proliferative potential as well as fewer exhausted T cells. If applied to the manufacture of LB2102, this would be the first application of the T-Charge platform to a cell therapy candidate targeting solid tumors, according to a company press release.

Cheers!!!!!!!!!!!!!!!!!

[canadafan]

Onc has been involved with CAR-t opportunities for over a year. They have 3 potential phase 3 co- development with Roche. The PanCan project has been re- evaluated, yet the $5 million grant still intact. Beyond that all guesswork. We are told " multiple discussions with multiple potential pharma partners" So! with the recent strong evidence from the Roche/ Onc , " goblet"

[venture009]

The share price has been under pressure ever since the release of positive trial results and of course the unexpected PanCan announcement. Over the years this management has had too many missteps and should be replaced with a management intent on selling the company, The SP is way off it's 52 week high. Coffey has suggested that they are in talks with BP but the market appears to be

[Noteable]

Shills for particular management should just Shut Up already. 

[Noteable]

de Guttadauro has done absolutely nothing  

[inthno]

I thought we were supposed to have a CarT deal 2 years ago or at least that was the expectations and just how long does it take to reproduce mice results given that companies supposedly signed mta's a long time ago to try to reproduce the said results. As for Andrew, nice guy but has yet to prove himself to shareholders. The company cannot really change directions on anything now, they just

[Noteable]

nice guys are nothing other than self promoters. Full of fluff and nothing more.

[Buckhenry]

Many companies have died on the vine because they did not understand and have the right folks to bring a product to market. You may have the best widget in the world but it's worthless if you don't know how to bring it to Market 

[Jf4270393]

Your point is a generality and hopefully Oncolytics will do shareholders the best interests. I do feel that the company has some very experienced management, and hope results are forthcoming in 2023.

[Buckhenry]

I don't say things for folks to like... I say them cause they need to be said. If they had done any marketing  at all we should be closer to $10  not a buck fifty. 

[Azzak34]

You're the true trailblazer! I've been saying it the whole time.  Our drug is great and management has underperformed. It's been said multiple times. What has or hasn't happened isn't important.  If management doesn't sort themselves out there must be repercussions from the shareholders. 

[JohnnyYeg]

I am so f***ing pissed off with management for exactly that Azz - great product, but a bunch of girl scouts trying to market it like cookies. NO OFFENSE whatsoever to girl scouts - great product, but all they need to do is smile at you in their uniforms. Maybe that's Andrew's problem - he knocks on BPs door with a big Cheshire Cat grin on his face, or maybe dressing like Oliver Twist with

[Azzak34]

I hear ya mate, it's getting increasingly apparent our guys need to step aside. I was quite happy to wait for the bigger money but I'm beginning to think we take a lesser offer and get this to market.  Sorry to hear about the pup. 

[JohnnyYeg]

Thanks man...it's been a difficult few days, and thankfully puts this show in context.

[fox7mf]

There has to be something big coming by EOY. ONCY needs that partnership if they're to launch ph3 by June. If it's a buyout (please PLEASE), I can't imagine anything less than $3b-$4b. Chin up Johnny boy.

[Buckhenry]

A $10 big companies will take notice... at $1.50 your put down in the  last call rack in the shoe store. 

[Buckhenry]

Matt may continue until he runs out or can't raise anymore capital. The problem is there are other car-t players on the horizon. He is definitely rolling the dice here. 

[Noteable]

Matt and the rest of management can expect a big payout upon ONCYs acquisition .... so therefore they have an equally big incentive to get a deal done before 'he runs out', as you've uncunningly tried to plant. 

[Buckhenry]

Runs out of capital  or can't raise any capital... goofus 

[Noteable]

Neither should happen given their buy-out payment incentives that they built-in over time to their overall compensation packages.

[Noteable]

You seem to keep forgetting that whoever acquires ONCY will bring pelareorep to market by themselves. ONCY needs to just accelerate the Phase 3 clinical trial in metastatic pancreatic cancer and apply for an Accelerated Approval filing.

[fox7mf]

Good post Note. All that needs to be said.

[Noteable]

August 09, 2024 - Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged. The company’s CAR-T therapy Carvykti, partnered with Johnson & Johnson, is starting a launch in second-line multiple myeloma, as the two partners are busy expanding capacity at multiple manufacturing sites

[Noteable]

" At this point, there’s no sign that either GenScript or Legend will be added to the BIOSECURE Act’s list of target companies, which could be barred from contracting with the U.S. government and effectively pushed out of the U.S. market. But it’d be logical if J&J wanted to mitigate the risk by removing the Chinese tie and taking Legend’s operations into its own hands."

[Noteable]

Dr. Frank Zhang has served as the Chairman of Board of Directors of Legend Biotech since May 2015. Dr. Zhang has been the chairman, an executive director and chief executive officer of GenScript since 2015. He co-founded the GenScript group in 2002 and has been the director of various group companies prior to GenScript becoming the